| Literature DB >> 30606157 |
Taro Iwatsubo1,2, Ryu Ishihara3, Toshitaka Morishima4, Akira Maekawa1, Kentaro Nakagawa1, Masamichi Arao1, Masayasu Ohmori1, Hiroyoshi Iwagami1, Kenshi Matsuno1, Shuntaro Inoue1, Hiroko Nakahira1, Noriko Matsuura1, Satoki Shichijo1, Takashi Kanesaka1, Sachiko Yamamoto1, Yoji Takeuchi1, Koji Higashino1, Noriya Uedo1, Isao Miyashiro4, Kazuhide Higuchi2, Takashi Fujii5.
Abstract
BACKGROUND: Metachronous cancer in patients with head and neck cancer (HNC) is common and is associated with a poor prognosis. We aimed to evaluate the incidence of metachronous cancer at different sites according to age at diagnosis of index HNC.Entities:
Keywords: Cumulative incidence; Esophageal cancer; Head and neck cancer; Metachronous cancer; Young onset
Mesh:
Year: 2019 PMID: 30606157 PMCID: PMC6318848 DOI: 10.1186/s12885-018-5231-7
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1Flow diagram of enrollment in this study
Patient characteristics
| All cases, n | 1953 |
|---|---|
| Gender, male/female, n | 1588/365 |
| Age, median (range), year | 65 (12–97) |
| ≥ 65, n | 983 |
| < 65, n | 970 |
| Lesion location | |
| Oral cavity, n (%) | 514 (26) |
| Oropharynx, n (%) | 300 (15) |
| Hypopharynx, n (%) | 541 (28) |
| Larynx, n (%) | 598 (31) |
| Histological type | |
| Squamous cell carcinoma, n (%) | 1863 (95.4) |
| Malignant lymphoma, n (%) | 28 (1.4) |
| Basaloid squamous cell carcinoma, n (%) | 9 (0.4) |
| Verrucous carcinoma, n (%) | 8 (0.4) |
| Adenoid cystic carcinoma, n (%) | 7 (0.4) |
| Malignant melanoma, n (%) | 5 (0.3) |
| Neuroendocrine carcinoma, n (%) | 4 (0.2) |
| Papillary squamous cell carcinoma, n (%) | 3 (0.2) |
| Mucoepidermoid carcinoma, n (%) | 3 (0.2) |
| Others, n (%) | 14 (0.7) |
| Unknown, n (%) | 9 (0.4) |
Fig. 2Cumulative incidence of second primary cancers after index head and neck cancers according to cancer site
Incidence of metachronous cancer after head and neck cancer by age at diagnosis of index cancer
| Age ≥ 65 | Age < 65 | Total | |
|---|---|---|---|
| Esophageal cancer, n | 73 | 117 | 190 |
| Lung cancer, n | 37 | 28 | 65 |
| Other organs | |||
| Gastric cancer, n | 39 | 33 | 72 |
| Colorectal cancer, n | 17 | 18 | 35 |
| Liver cancer, n | 9 | 6 | 15 |
| Prostatic cancer, n | 7 | 4 | 11 |
| Thyroid cancer, n | 4 | 7 | 11 |
| Renal and ureter cancer, n | 8 | 2 | 10 |
| Breast cancer, n | 4 | 3 | 7 |
| Pancreatic cancer, n | 3 | 1 | 4 |
| Uterine cancer, n | 1 | 1 | 2 |
| Others, na | 5 | 6 | 11 |
| Total, n | 97 | 81 | 178 |
aOthers include 3 lymphomas (1 eye socket, 2 lymph nodes, and 1 unknown region), 2 myelomas, 1 ovarian cancer, 1 cancer of the maxillary sinus, 1 duodenal cancer, and 1 cancer of unknown primary origin
Fig. 3Cumulative incidence of metachronous (a) esophageal cancer, (b) lung cancer and (c) other organ cancers according to age at diagnosis of index head and neck cancers
Multivariate predictors for incidence of metachronous cancers after head and neck cancer
| All cancers | Esophageal cancer | Lung cancer | Other cancers | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | 95%CI | OR | 95%CI | OR | 95%CI | OR | 95%CI | ||||||
| Age | < 65 years | 1.20 | 0.95–1.52 | 0.131 | 1.75 | 1.27–2.41 | < 0.001 | 0.84 | 0.50–1.39 | 0.492 | 0.89 | 0.65–1.22 | 0.465 |
| ≥65 years | 1 | 1 | 1 | ||||||||||
| Sex | Male | 1.32 | 0.94–1.87 | 0.129 | 1.20 | 0.69–1.74 | 0.697 | 2.02 | 0.78–5.22 | 0.149 | 1.65 | 0.99–2.72 | 0.051 |
| Female | 1 | 1 | 1 | 1 | |||||||||
| Histological type | Squamous cell carcinoma | 3.63 | 1.30–10.1 | 0.014 | 7.50 | 1.02–55.2 | 0.048 | 2.17 | 0.67–7.05 | 0.196 | |||
| Others | 1 | 1 | Not applicablea | 1 | |||||||||
| Lesion location | Oral cavity | 1 | 1 | 1 | 1 | ||||||||
| Oropharynx | 1.08 | 0.68–1.72 | 0.731 | 1.40 | 0.72–2.71 | 0.325 | 0.33 | 0.07–1.56 | 0.162 | 0.88 | 0.50–1.57 | 0.669 | |
| Hypopharynx | 3.17 | 2.25–4.48 | < 0.001 | 5.88 | 3.62–9.55 | < 0.001 | 2.47 | 1.13–5.42 | 0.024 | 1.20 | 0.76–1.88 | 0.439 | |
| Larynx | 1.92 | 1.34–2.74 | < 0.001 | 1.53 | 0.88–2.68 | 0.132 | 2.14 | 0.97–4.73 | 0.061 | 1.42 | 0.91–2.20 | 0.122 | |
OR Odds ratio, CI confidence interval
aHistological type was excluded from the multivariate analysis for metachronous lung cancer which developed only in patients with head and neck squamous cell carcinoma